Xeomin<sup>®</sup>, a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury

Xeomin<sup>®</sup> is a commercial formulation of botulinum neurotoxin type A (BoNT/A) clinically authorized for treating neurological disorders, such as blepharospasm, cervical dystonia, limb spasticity, and sialorrhea. We have previously demonstrated that spinal injection of laboratory...

Full description

Bibliographic Details
Published in:Toxins
Main Authors: Valentina Mastrorilli, Federica De Angelis, Valentina Vacca, Flaminia Pavone, Siro Luvisetto, Sara Marinelli
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Subjects:
botulinum neurotoxin
spinal cord injury
regeneration
motor recovery
sciatic static index
neuropathic pain
Online Access:https://www.mdpi.com/2072-6651/15/4/248

Internet

https://www.mdpi.com/2072-6651/15/4/248

Similar Items